• 1
    Ishizu H, Uchino J, Sato N, Aoki S, Suzuki K, Kuribayashi H. Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. HEPATOLOGY 1997; 25: 528531.
  • 2
    WHO Informal Working Group on Echinococcosis. Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull World Health Organ 1996; 74: 231242.
  • 3
    Ammann RW, Ilitsch N, Marincek B, Freiburghaus AU. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. HEPATOLOGY 1994; 19: 735742.
  • 4
    Schantz PM, Wilson JF, Wahlquist SP, Boss LP, Rausch RL. Serologic tests for diagnosis and post-treatment evaluation of patients with alveolar hydatid disease (Echinococcus multilocularis). Am J Trop Med Hyg 1983; 32: 13811386.
  • 5
    Wilson JF, Rausch RL, McMahon BJ, Schantz PM. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 1992; 15: 234249.
  • 6
    Ammann RW, Fleiner-Hoffmann A, Grimm F, Eckert J. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J Hepatol 1998; 29: 994998.
  • 7
    Reuter S, N̈ussle K, Kolokythas O, Haug U, Rieber A, Kern P, Kratzer W. Alveolar iver echinococcosis: a comparative study of three imaging techniques. Infection 2001; 29: 119125.
  • 8
    Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, Yamaoka Y, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35: 19651969.
  • 9
    Bangerter M, Moog F, Griesshammer M, Merkle E, Hafner M, Ellenrieder V, Reske SN, et al. Usefulness of FDG-PET in diagnosing primary lymphoma of the liver. Int J Hematol 1997; 66: 517520.
  • 10
    Schroter G, Schneider EJ, Schwaiger M. Assessment of tissue viability with fluorine-18-fluoro-2-deoxyglucose (FDG) and carbon-11-acetate PET imaging. Herz 1994; 19: 4250.
  • 11
    Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, Nakamura K, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med 1996; 10: 185191.
  • 12
    De Winter F, Vogelaers D, Gemmel F, Dierckx RA. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur J Clin Microbiol Infect Dis 2002; 21: 247257.
  • 13
    Alavi A, Zhuang H. Finding infection—help from PET. Lancet 2001; 358: 1386.
  • 14
    Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000; 27: 822832.
  • 15
    Reuter S, Schirrmeister H, Kratzer W, Dreweck C, Reske SN, Kern P. Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Infect Dis 1999; 29: 11571163.
  • 16
    Gottstein B, Jacquier P, Bresson-Hadni S, Eckert J. Improved primary immunodiagnosis of alveolar echinococcosis in humans by an enzyme-linked immunosorbent assay using the Em2plus antigen. J Clin Microbiol 1993; 31: 373376.
  • 17
    Schmidlin P. Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med 1994; 21: 930936.
  • 18
    Ammann RW, Hirsbrunner R, Cotting J, Steiger U, Jacquier P, Eckert J. Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echinococcosis (preliminary results). Am J Trop Med Hyg 1990; 43: 506515.
  • 19
    Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother 2000; 46: 451456.
  • 20
    Rausch RL, Wilson JF, McMahon BJ, O'Gorman MA. Consequences of continuous mebendazole therapy in alveolar hydatid disease—with a summary of a ten-year clinical trial. Ann Trop Med Parasitol 1986; 80: 403419.
  • 21
    Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, Taniguchi M, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39: 10161020.
  • 22
    Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33: 333339.
  • 23
    Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 18111817.
  • 24
    Choji K, Fujita N, Chen M, Spiers AS, Morita Y, Shinohara M, Nojima T, et al. Alveolar hydatid disease of the liver: computed tomography and transabdominal ultrasound with histopathological correlation. Clin Radiol 1992; 46: 97103.
  • 25
    Didier D, Weiler S, Rohmer P, Lassegue A, Deschamps JP, Vuitton D, Miguet JD, et al. Hepatic alveolar echinococcosis: correlative US and CT study. Radiology 1985; 154: 179186.
  • 26
    Liu YH, Wang XG, Chen YT, Yao YQ. Computer tomography of liver in alveolar echinococcosis treated with albendazole. Trans R Soc Trop Med Hyg 1993; 87: 319321.
  • 27
    Ammann RW, Tschudi K, von Ziegler M, Meister F, Cotting J, Eckert J, Witassek F, et al. [ Long term course of alveolar echinococcosis in 60 patients treated by mebendazole (1976-1985)]. Klin Wochenschr 1988; 66: 10601073.
  • 28
    Rausch RL, Wilson JF, Schantz PM, McMahon BJ. Spontaneous death of Echinococcus multilocularis: cases diagnosed serologically (by Em2 ELISA) and clinical significance. Am J Trop Med Hyg 1987; 36: 576585.
  • 29
    Gottstein B, Mesarina B, Tanner I, Ammann RW, Wilson JF, Eckert J, Lanier A. Specific cellular and humoral immune responses in patients with different long-term courses of alveolar echinococcosis (infection with Echinococcus multilocularis). Am J Trop Med Hyg 1991; 45: 734742.
  • 30
    Jura H, Bader A, Frosch M. In vitro activities of benzimidazoles against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 1998; 42: 10521056.
  • 31
    Rausch RL, Wilson JF, McMahon BJ, O'Gorman MA. Consequences of continuous mebendazole therapy in alveolar hydatid disease—with a summary of a ten-year clinical trial. Ann Trop Med Parasitol 1986; 80: 403419.
  • 32
    Reuter S, Merkle M, Brehm K, Kern P, Manfras B. Effect of amphotericin B on larval growth of Echinococcus multilocularis. Antimicrob Agents Chemother 2003; 47: 620625.
  • 33
    Eckert J. Prospects for treatment of the metacestode stage of Echinococcus. In: ThompsonRCA, ed. The Biology of Echinococcus and Hydatid Disease. London: George Allen & Unwin, 1986: 250284.
  • 34
    Vuitton DA, Guerret-Stocker S, Carbillet JP, Mantion G, Miguet JP, Grimaud JA. Collagen immunotyping of the hepatic fibrosis in human alveolar echinococcosis. Z Parasitenkd 1986; 72: 97104.
  • 35
    Chakrabarti R, Jung CY, Lee TP, Liu H, Mookerjee BK. Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol 1994; 152: 26602668.
  • 36
    Gamelli RL, Liu H, He LK, Hofmann CA. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996; 59: 639647.